Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...

Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

The $599 price is also vastly lower than the other GLP-1s offered on Hims & Hers: it provides Ozempic for $1,799 a month, Mounjaro for $1,899 a month and Zepbound for $1,899 a month. This is a ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer ...

Hims & Hers Health announced on Tuesday it will bundle ... along with Novo's Ozempic and Eli Lilly's Zepbound and Mounjaro. Get a brief on the top business stories of the week, plus CEO interviews ...

Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including ...